Amgen has announced to purchase
20.5% of the stake in Chinese-American drug company BeiGene.
As per the deal signed, Amgen will develop and commercialize around two dozen of its on-market as well as experimental drug compounds for the treatment of cancer in China.
The shares purchased are worth USD 2.7
billion, and Amgen has reserved a set on BeiGene’s board.
BeiGene will be able to sell three drugs Xgeva, Kyprolis and Blincyto in the Chinese market. The profit will be equally split between the two countries. BeiGene will also manufacture 20 of the experimental drugs of Amgen. BeiGene will spend around USD 1.25 Billion for the process and Amgen will help fu...
